Canadian researchers developed a calculator that can predict the chances of those 55 and up getting diagnosed with dementia.
You can count on Canadian researchers to build a calculator that can predict your chances of developing dementia.
Researchers at the Ottawa Hospital, the University of Ottawa, the Bruyère Research Institute and ICES developed an online calculator empowering people over 55 to understand how they can reduce the risk of being diagnosed with dementia in the next five years. This is the first tool designed to predict dementia, which refers to loss of memory and other thinking abilities that interferes with daily life, on a population level. Over 6.2 million Americans over age 65 live with dementia and, in Canada, more than 76,000 new cases of dementia are diagnosed yearly. During the COVID-19 pandemic, Alzheimer’s and dementia deaths increased 16% in the US.
The calculator — or the Dementia Population Risk Tool (DemPoRT) — can estimate the number of new cases in the community, identify higher-risk populations and inform dementia prevention strategies.
The first disease modifying drug for Alzheimer’s disease will be priced at a $56,000 a year for an average weight patient, setting the drug up to be a mega blockbuster if Biogen can get it reimbursed.
Biogen, Inc. and Eisai Co., Ltd. won a groundbreaking approval for Aduhelm (aducanumab) as the first disease-modifying drug for Alzheimer’s disease, and now attention turns to the commercial ramp. The big question is if the companies can convince patients, physicians and payers that the uncertain efficacy of the drug justifies the price Biogen has set.
Aduhelm was granted an accelerated approval by the US Food and Drug Administration on 7 June in a controversial decision that had Alzheimer’s patient advocates, investors and the biopharma community riveted. In recognition of the limited clinical trial data supporting the approval, FDA agreed only to an accelerated approval and said it would require a confirmatory trial to prove efficacy or else it will pull the drug from the market – but getting that information will take years.
U.S. regulators on Monday approved Biogen Inc’s (BIIB.O) aducanumab as the first treatment to attack a likely cause of Alzheimer’s disease despite controversy over whether the clinical evidence proves the drug works, sending its shares soaring.
Biogen said it has priced the drug, to be sold as Aduhelm, at $56,000 per year. After jumping more than 50%, Biogen shares closed up 38.3% at $395.85 – their highest closing level in over six years. U.S. traded shares of Japanese partner Eisai Co (4523.T) rose 56% to $116.03. Aducanumab works by removing sticky deposits of a protein called amyloid beta from the brains of patients in earlier stages of Alzheimer’s in order to stave off its ravages, which include memory loss and the inability to care for oneself.
“This is good news for patients with Alzheimer’s disease. We’ve not had a disease modifying therapy approved ever,” said Dr. Ronald Petersen, an Alzheimer’s disease expert at the Mayo Clinic. However, he cautioned, “This is not a cure. It’s hoped that this will slow the progression of the disease.”
The latest update to the Fitbit app contains the beginnings of nighttime snoring and noise detection, along with a cute way to think about your sleeping habits.
About APK Insight: In this “APK Insight” post, we’ve decompiled the latest version of an application that Google uploaded to the Play Store. When we decompile these files (called APKs, in the case of Android apps), we’re able to see various lines of code within that hint at possible future features. Keep in mind that Google may or may not ever ship these features, and our interpretation of what they are may be imperfect. We’ll try to enable those that are closer to being finished, however, to show you how they’ll look in case that they do ship. With that in mind, read on.